US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Polyrizon Ltd.

12.56

+0.05000.40%

Post-market: 11.60-0.9600-7.64%16:56 EDT

Volume:134.41K

Turnover:1.66M

Market Cap:26.17M

PE:-2.56

High:13.28

Open:12.00

Low:11.95

Close:12.51

52wk High:18.20

52wk Low:2.88

Shares:2.08M

Float Shares:1.65M

Volume Ratio:1.17

T/O Rate:8.15%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.9017

ROE:-25.38%

ROA:-28.95%

PB:1.25

PE(LYR):- -

Loading ...

Overview Company News Filings

Polyrizon announces $4.0M registered direct offering

Polyrizon Sells $4 Million in Unregistered Warrants in Private Placement

Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement

THOMSON REUTERS

Polyrizon completes all five U.S. site contracts for Nasarix allergy study

Polyrizon Completes Contracts for Five U.S. Sites in Nasarix First-in-Human Seasonal Allergic Rhinitis Trial

Polyrizon Completes US Clinical Site Network for Nasarix Seasonal Allergic Rhinitis Trial

Polyrizon Completes Clinical Site Network for Nasarix™ Study and Advances Toward Patient Enrollment

THOMSON REUTERS

Polyrizon Adopts New Executive, Director Pay Policy with Bonus, Equity Caps

Polyrizon Says Nasarix Allergy Nasal Spray Meets All Biocompatibility Safety Standards in Testing

MT Newswires Live

Polyrizon announces results from Nasarix biocompatibility evaluation program

Polyrizon Flags Release on Nasarix Biocompatibility Program Results

Polyrizon Announces Successful Results for Nasarix™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial

THOMSON REUTERS

Polyrizon Receives Approval for Human Trial of Nasarix Nasal Spray for Allergic Rhinitis

MT Newswires Live

Polyrizon receives central IRB approval for Nasarix

Polyrizon Wins Central IRB Clearance to Start First Nasarix Allergy Blocker Human Trial

Polyrizon Makes Strong Progress: Receives Central Irb Approval for Its Allergy Blocker Clinical Trial

THOMSON REUTERS

Polyrizon says U.S. publishes patent application for Trap & Target nasal drug delivery platform

Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

THOMSON REUTERS

Polyrizon Signs Agreements for Nasarix Human Study

MT Newswires Live

Polyrizon - Agrees With European Medical Center and Cro for Nasarix Human Study

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/PLRZ/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PLRZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLRZ\",,,,,undefined,":{"symbol":"PLRZ","market":"US","secType":"STK","nameCN":"Polyrizon Ltd.","latestPrice":12.56,"timestamp":1788465600000,"preClose":12.51,"halted":0,"volume":134411,"hourTrading":{"tag":"盘后","latestPrice":11.6,"preClose":12.56,"latestTime":"16:56 EDT","volume":1077,"amount":13076.280261000002,"timestamp":1788468975708,"change":-0.96,"changeRate":-0.076433,"amplitude":0.134554},"delay":0,"changeRate":0.003996802557953694,"floatShares":1648899,"shares":2083979,"eps":-4.901672,"marketStatus":"Post-Mkt","change":0.05,"latestTime":"09-03 18:20:36 EDT","open":12,"high":13.28,"low":11.95,"amount":1659186.588608,"amplitude":0.106315,"askPrice":14,"askSize":42,"bidPrice":11.73,"bidSize":10,"shortable":0,"etf":0,"ttmEps":-4.901672,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788480000000},"marketStatusCode":4,"adr":0,"listingDate":1730174400000,"exchange":"NASDAQ","adjPreClose":12.51,"preHourTrading":{"tag":"盘前","latestPrice":11.18,"preClose":12.51,"latestTime":"09:21 EDT","volume":875,"amount":9758.199499999999,"timestamp":1788441704612,"change":-1.33,"changeRate":-0.106315,"amplitude":0.131894},"postHourTrading":{"tag":"盘后","latestPrice":11.6,"preClose":12.56,"latestTime":"16:56 EDT","volume":1077,"amount":13076.280261000002,"timestamp":1788468975708,"change":-0.96,"changeRate":-0.076433,"amplitude":0.134554},"volumeRatio":1.168046},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLRZ\",,,,,undefined,":{"symbol":"PLRZ","floatShares":1648899,"roa":"-28.95%","roe":"-25.38%","lyrEps":0,"volumeRatio":1.168046,"shares":2083979,"dividePrice":0,"high":13.28,"amplitude":0.106315,"preClose":12.51,"low":11.95,"week52Low":2.88,"pbRate":"1.25","week52High":18.2,"institutionHeld":0,"latestPrice":12.56,"committee":-0.615385,"eps":-4.901672,"divideRate":0,"volume":134411,"delay":0,"ttmEps":-4.901672,"open":12,"prevYearClose":8.49,"prevWeekClose":13.145,"prevMonthClose":14.51,"prevQuarterClose":12.52,"fiveDayClose":12.8,"twentyDayClose":11.49,"sixtyDayClose":11.45},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PLRZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-28","symbol":"PLRZ","defaultRemindTime":1764340200000,"type":"split","dateTimestamp":1764306000000,"forFactor":6,"toFactor":1,"ratio":6},{"market":"US","date":"2025-05-27","symbol":"PLRZ","defaultRemindTime":1748352600000,"type":"split","dateTimestamp":1748318400000,"forFactor":250,"toFactor":1,"ratio":250}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PLRZ\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PLRZ\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PLRZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PLRZ","date":"2026-09-02","current":-2.562391,"percent":0.346405,"low":-29.515607,"twenty":-11.529533,"median":-6.632,"eighty":-3.08548,"high":-0.011381,"avg":-7.98059,"sd":6.060083,"marketCap":26879737},"quantilePoints":[{"date":"2024-10-31","current":-13.097935,"twenty":-22.948538,"median":-13.097935,"eighty":-12.489816,"marketCap":7858761},{"date":"2024-11-08","current":-3.903419,"twenty":-12.692522,"median":-4.690878,"eighty":-4.316449,"marketCap":3891709},{"date":"2024-11-15","current":-2.661127,"twenty":-9.219549,"median":-4.249136,"eighty":-3.530862,"marketCap":2653144},{"date":"2024-11-22","current":-2.985655,"twenty":-4.737156,"median":-3.736612,"eighty":-3.09924,"marketCap":2976698},{"date":"2024-11-29","current":-3.042447,"twenty":-4.451075,"median":-3.375089,"eighty":-3.037515,"marketCap":3033320},{"date":"2024-12-06","current":-3.212824,"twenty":-4.383762,"median":-3.342636,"eighty":-3.042447,"marketCap":3203186},{"date":"2024-12-13","current":-3.375088,"twenty":-4.191157,"median":-3.358862,"eighty":-3.047315,"marketCap":3364963},{"date":"2024-12-20","current":-7.561496,"twenty":-4.383762,"median":-3.375088,"eighty":-3.07146,"marketCap":7538812},{"date":"2024-12-27","current":-5.744141,"twenty":-5.095085,"median":-3.407542,"eighty":-3.090153,"marketCap":5726909},{"date":"2025-01-03","current":-5.938858,"twenty":-6.101122,"median":-3.569805,"eighty":-3.132991,"marketCap":5921041},{"date":"2025-01-10","current":-4.997727,"twenty":-6.159537,"median":-3.796975,"eighty":-3.146231,"marketCap":4982734},{"date":"2025-01-17","current":-6.142316,"twenty":-6.098128,"median":-3.933764,"eighty":-3.167391,"marketCap":6123889},{"date":"2025-01-24","current":-5.889893,"twenty":-6.192801,"median":-4.333277,"eighty":-3.193353,"marketCap":5872223},{"date":"2025-01-31","current":-5.553327,"twenty":-6.125488,"median":-4.527162,"eighty":-3.214122,"marketCap":5536667},{"date":"2025-02-07","current":-4.552045,"twenty":-6.087615,"median":-4.738105,"eighty":-3.227753,"marketCap":4538389},{"date":"2025-02-14","current":-4.711914,"twenty":-6.064471,"median":-4.705652,"eighty":-3.245278,"marketCap":4697778},{"date":"2025-02-21","current":-4.522596,"twenty":-6.049761,"median":-4.627772,"eighty":-3.258259,"marketCap":4509028},{"date":"2025-02-28","current":-3.707687,"twenty":-6.000655,"median":-4.535397,"eighty":-3.316674,"marketCap":3696564},{"date":"2025-03-07","current":-3.460732,"twenty":-5.929065,"median":-4.501561,"eighty":-3.241954,"marketCap":3450350},{"date":"2025-03-14","current":-1.846098,"twenty":-5.873065,"median":-4.396383,"eighty":-3.213473,"marketCap":2852222},{"date":"2025-03-21","current":-1.508371,"twenty":-5.793429,"median":-4.291207,"eighty":-3.160314,"marketCap":2330433},{"date":"2025-03-28","current":-1.353625,"twenty":-5.705978,"median":-3.977976,"eighty":-3.07146,"marketCap":2091350},{"date":"2025-04-04","current":-0.974631,"twenty":-5.536499,"median":-3.903419,"eighty":-3.030526,"marketCap":1505805},{"date":"2025-04-11","current":-0.980061,"twenty":-5.4398,"median":-3.702849,"eighty":-2.640357,"marketCap":1514194},{"date":"2025-04-17","current":-0.985491,"twenty":-5.322255,"median":-3.619184,"eighty":-1.846098,"marketCap":1522583},{"date":"2025-04-25","current":-0.947483,"twenty":-5.174691,"median":-3.5049,"eighty":-1.520317,"marketCap":1463861},{"date":"2025-05-02","current":-0.687943,"twenty":-5.159991,"median":-3.434137,"eighty":-1.353625,"marketCap":1062872},{"date":"2025-05-09","current":-2.602277,"twenty":-5.095085,"median":-3.375088,"eighty":-1.466019,"marketCap":4020518},{"date":"2025-05-16","current":-0.039201,"twenty":-5.02132,"median":-3.354145,"eighty":-1.299871,"marketCap":60566},{"date":"2025-05-23","current":-0.018499,"twenty":-5.006408,"median":-3.310183,"eighty":-1.057434,"marketCap":28581},{"date":"2025-05-30","current":-0.022023,"twenty":-4.999463,"median":-3.245278,"eighty":-1.021327,"marketCap":34025},{"date":"2025-06-06","current":-0.014912,"twenty":-4.937359,"median":-3.214447,"eighty":-0.978975,"marketCap":23039},{"date":"2025-06-13","current":-0.018851,"twenty":-4.922267,"median":-3.183486,"eighty":-0.945854,"marketCap":29125},{"date":"2025-06-20","current":-0.013358,"twenty":-4.871782,"median":-3.155299,"eighty":-0.895899,"marketCap":20638},{"date":"2025-06-27","current":-2.431375,"twenty":-4.817057,"median":-3.116926,"eighty":-0.895899,"marketCap":3756474},{"date":"2025-07-03","current":-2.428961,"twenty":-4.79003,"median":-3.054617,"eighty":-0.90676,"marketCap":3752744},{"date":"2025-07-11","current":-2.469311,"twenty":-4.75787,"median":-3.036282,"eighty":-0.929565,"marketCap":3815085},{"date":"2025-07-18","current":-3.343916,"twenty":-4.728069,"median":-3.039365,"eighty":-0.942596,"marketCap":5166350},{"date":"2025-07-25","current":-4.793774,"twenty":-4.784488,"median":-3.066787,"eighty":-0.954976,"marketCap":7406381},{"date":"2025-08-01","current":-9.134632,"twenty":-4.922267,"median":-3.137242,"eighty":-0.969039,"marketCap":14113006},{"date":"2025-08-08","current":-8.476938,"twenty":-5.004125,"median":-3.155299,"eighty":-0.973817,"marketCap":13096869},{"date":"2025-08-15","current":-8.18463,"twenty":-5.134029,"median":-3.19779,"eighty":-0.976803,"marketCap":12645253},{"date":"2025-08-22","current":-7.746168,"twenty":-5.410414,"median":-3.21607,"eighty":-0.982233,"marketCap":11967829},{"date":"2025-08-29","current":-7.600014,"twenty":-5.856236,"median":-3.245278,"eighty":-0.987228,"marketCap":11742021},{"date":"2025-09-05","current":-7.819245,"twenty":-6.049761,"median":-3.325781,"eighty":-0.992223,"marketCap":12080733},{"date":"2025-09-12","current":-7.143282,"twenty":-6.209629,"median":-3.343916,"eighty":-1.006667,"marketCap":11036370},{"date":"2025-09-19","current":-10.354516,"twenty":-6.696876,"median":-3.375088,"eighty":-1.026648,"marketCap":11742021},{"date":"2025-09-26","current":-11.070023,"twenty":-7.035762,"median":-3.443585,"eighty":-1.030557,"marketCap":12553406},{"date":"2025-10-03","current":-11.383325,"twenty":-7.364852,"median":-3.487865,"eighty":-1.042883,"marketCap":12908691},{"date":"2025-10-10","current":-13.054272,"twenty":-7.512322,"median":-3.569805,"eighty":-1.058791,"marketCap":14803545},{"date":"2025-10-17","current":-11.174457,"twenty":-7.59231,"median":-3.644879,"eighty":-1.068565,"marketCap":12671834},{"date":"2025-10-24","current":-11.278891,"twenty":-7.731553,"median":-3.707687,"eighty":-1.123948,"marketCap":12790262},{"date":"2025-10-31","current":-10.75672,"twenty":-7.950784,"median":-3.905854,"eighty":-1.280758,"marketCap":12198121},{"date":"2025-11-07","current":-9.567215,"twenty":-8.038476,"median":-3.996712,"eighty":-1.310622,"marketCap":10849222},{"date":"2025-11-14","current":-8.045608,"twenty":-8.360015,"median":-4.312242,"eighty":-1.376104,"marketCap":9123720},{"date":"2025-11-21","current":-6.109399,"twenty":-8.170015,"median":-4.417419,"eighty":-1.474489,"marketCap":6928059},{"date":"2025-11-28","current":-5.587228,"twenty":-8.111553,"median":-4.501561,"eighty":-1.508371,"marketCap":6335917},{"date":"2025-12-05","current":-25.23826,"twenty":-8.403861,"median":-4.535397,"eighty":-1.515701,"marketCap":28620187},{"date":"2025-12-12","current":-21.591766,"twenty":-8.696169,"median":-4.627772,"eighty":-1.520317,"marketCap":24485063},{"date":"2025-12-19","current":-17.597159,"twenty":-9.06593,"median":-4.711914,"eighty":-1.541633,"marketCap":19955178},{"date":"2025-12-26","current":-13.245735,"twenty":-9.27961,"median":-4.754698,"eighty":-1.546299,"marketCap":15020663},{"date":"2026-01-02","current":-14.777436,"twenty":-10.201257,"median":-4.798393,"eighty":-1.579229,"marketCap":16757612},{"date":"2026-01-09","current":-23.341039,"twenty":-10.662157,"median":-4.922267,"eighty":-1.630419,"marketCap":26468738},{"date":"2026-01-16","current":-21.842963,"twenty":-11.038692,"median":-4.999213,"eighty":-1.702674,"marketCap":24769920},{"date":"2026-01-23","current":-22.02569,"twenty":-11.165081,"median":-5.003554,"eighty":-1.780942,"marketCap":24977133},{"date":"2026-01-30","current":-18.441421,"twenty":-11.278891,"median":-5.035187,"eighty":-1.871075,"marketCap":20912571},{"date":"2026-02-06","current":-17.471559,"twenty":-11.383325,"median":-5.167341,"eighty":-1.959036,"marketCap":19812748},{"date":"2026-02-13","current":-19.664289,"twenty":-11.445985,"median":-5.322255,"eighty":-2.161828,"marketCap":22299304},{"date":"2026-02-20","current":-19.158274,"twenty":-11.780175,"median":-5.500199,"eighty":-2.356399,"marketCap":21725483},{"date":"2026-02-27","current":-19.24261,"twenty":-12.048622,"median":-5.587228,"eighty":-2.377712,"marketCap":21821120},{"date":"2026-03-06","current":-19.130163,"twenty":-12.337157,"median":-5.805751,"eighty":-2.404957,"marketCap":21693605},{"date":"2026-03-13","current":-21.491564,"twenty":-13.089202,"median":-5.977481,"eighty":-2.428961,"marketCap":24371434},{"date":"2026-03-20","current":-18.975548,"twenty":-13.87234,"median":-6.068669,"eighty":-2.429444,"marketCap":21518271},{"date":"2026-03-27","current":-6.571741,"twenty":-14.681705,"median":-6.104823,"eighty":-2.432754,"marketCap":21916757},{"date":"2026-04-02","current":-6.133576,"twenty":-14.29878,"median":-6.093857,"eighty":-2.438272,"marketCap":20455475},{"date":"2026-04-10","current":-5.228861,"twenty":-14.168236,"median":-6.058175,"eighty":-2.459999,"marketCap":17438252},{"date":"2026-04-17","current":-5.848317,"twenty":-13.976774,"median":-5.969011,"eighty":-2.460689,"marketCap":19504138},{"date":"2026-04-24","current":-7.906455,"twenty":-13.454603,"median":-6.058175,"eighty":-2.469311,"marketCap":26368026},{"date":"2026-05-01","current":-8.924253,"twenty":-13.245735,"median":-6.093519,"eighty":-2.483106,"marketCap":29762383},{"date":"2026-05-08","current":-7.936411,"twenty":-13.245735,"median":-6.109399,"eighty":-2.496901,"marketCap":26467930},{"date":"2026-05-15","current":-8.430332,"twenty":-13.097935,"median":-6.18242,"eighty":-2.517594,"marketCap":28115156},{"date":"2026-05-22","current":-7.100113,"twenty":-13.054272,"median":-6.295839,"eighty":-2.548287,"marketCap":23678877},{"date":"2026-05-29","current":-9.261017,"twenty":-12.817554,"median":-6.483666,"eighty":-2.548563,"marketCap":30885492},{"date":"2026-06-05","current":-7.184304,"twenty":-12.577356,"median":-6.653598,"eighty":-2.591548,"marketCap":23959654},{"date":"2026-06-12","current":-6.49955,"twenty":-12.378931,"median":-6.640969,"eighty":-2.628587,"marketCap":21675999},{"date":"2026-06-18","current":-7.425652,"twenty":-12.330195,"median":-6.571741,"eighty":-2.650742,"marketCap":24764549},{"date":"2026-06-26","current":-6.409746,"twenty":-12.260573,"median":-6.632,"eighty":-2.70965,"marketCap":21376504},{"date":"2026-07-02","current":-7.116951,"twenty":-12.177025,"median":-6.653598,"eighty":-2.796579,"marketCap":23735032},{"date":"2026-07-10","current":-8.059891,"twenty":-12.10238,"median":-6.750178,"eighty":-2.921331,"marketCap":26879737},{"date":"2026-07-17","current":-7.296559,"twenty":-12.01284,"median":-7.006752,"eighty":-2.995391,"marketCap":24334024},{"date":"2026-07-24","current":-8.593101,"twenty":-11.905496,"median":-7.027147,"eighty":-3.017632,"marketCap":28657992},{"date":"2026-07-31","current":-6.522001,"twenty":-11.884609,"median":-7.027147,"eighty":-3.030526,"marketCap":21750873},{"date":"2026-08-07","current":-6.449035,"twenty":-11.801062,"median":-6.876942,"eighty":-3.037515,"marketCap":21507533},{"date":"2026-08-14","current":-6.033693,"twenty":-11.780175,"median":-6.701609,"eighty":-3.042447,"marketCap":20122366},{"date":"2026-08-21","current":-5.887762,"twenty":-11.696628,"median":-6.632,"eighty":-3.047315,"marketCap":19635685},{"date":"2026-08-28","current":-7.184304,"twenty":-11.654854,"median":-6.571741,"eighty":-3.07146,"marketCap":23959654},{"date":"2026-09-02","current":-8.059891,"twenty":-11.529533,"median":-6.632,"eighty":-3.08548,"marketCap":26879737}],"updateTime":1788474036266},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PLRZ\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664872110","title":"Polyrizon announces $4.0M registered direct offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2664872110","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664872110?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:55","pubTimestamp":1788440156,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) announced that it has entered into definitive agreements with a single institutional investor for the purchase and sale of its Ord...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-announces-4-0m-registered-direct-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-announces-4-0m-registered-direct-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664787253","title":"Polyrizon Sells $4 Million in Unregistered Warrants in Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2664787253","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664787253?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:50","pubTimestamp":1788439829,"startTime":"0","endTime":"0","summary":"Polyrizon sells $4 million in unregistered warrants in private placementPolyrizon set a concurrent private placement with one institutional investor alongside a registered direct offering, targeting g","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL1MRMmL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00B3QW5Z07.USD","IE00BQXX3C00.GBP","BK4139","IE00BN0W2T93.GBP","BK4588","PLRZ","SG9999014005.SGD","NDAQ","IE00BQXX3F31.USD","IE00BQXX3D17.EUR","IE00BGHQF748.EUR","SG9999014013.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","IE00BN0W2W23.USD","BK4585","SG9999014021.USD","LU2210149790.SGD","LU2095319765.USD","BCDF","IE00BKPKM429.USD","SG9999014039.USD","IE00BN0W2V16.EUR","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664587872","title":"Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2664587872","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664587872?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:50","pubTimestamp":1788439800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUA8S1NGF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881287","title":"Polyrizon completes all five U.S. site contracts for Nasarix allergy study","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881287","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664881287?lang=en_us&edition=fundamental","pubTime":"2026-09-02 21:16","pubTimestamp":1788354960,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) announced that it has completed contracting with the fourth and fifth clinical sites participating in its clinical study of Nasari...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-completes-all-five-u-s-site-contracts-for-nasarix-allergy-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-completes-all-five-u-s-site-contracts-for-nasarix-allergy-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664481644","title":"Polyrizon Completes Contracts for Five U.S. Sites in Nasarix First-in-Human Seasonal Allergic Rhinitis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664481644","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664481644?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:32","pubTimestamp":1788348775,"startTime":"0","endTime":"0","summary":"Polyrizon completes contracts for five U.S. sites in NASARIX first-in-human seasonal allergic rhinitis trialPolyrizon completed contracts for all five U.S. sites for a first-in-human trial of NASARIX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL6VgVp8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3C00.GBP","BK4588","IE00BN0W2V16.EUR","LU2210150020.SGD","IE00BN0W2W23.USD","SG9999014013.SGD","BK4139","BK4112","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014021.USD","SG9999014005.SGD","NDAQ","PLRZ","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","LU2210149790.SGD","IE00BQXX3F31.USD","IE00BGHQF748.EUR","LU2095319765.USD","BCDF","LU0314104364.USD","SG9999014039.USD","IE00BQXX3D17.EUR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660928743","title":"Polyrizon Completes US Clinical Site Network for Nasarix Seasonal Allergic Rhinitis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660928743","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660928743?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:30","pubTimestamp":1787232620,"startTime":"0","endTime":"0","summary":"Polyrizon completes US clinical site network for NASARIX seasonal allergic rhinitis trialPolyrizon completed contracting for all five U.S. sites for its first-in-human NASARIX Allergy Blocker study in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDLhQF5c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4585","IE00BGHQF748.EUR","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014039.USD","IE00BKPKM429.USD","BCDF","LU0314104364.USD","IE00BN0W2T93.GBP","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","PLRZ","BK4139","IE00BQXX3F31.USD","BK4112","SG9999014021.USD","NDAQ","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","SG9999014013.SGD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660871352","title":"Polyrizon Completes Clinical Site Network for Nasarix™ Study and Advances Toward Patient Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2660871352","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660871352?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:30","pubTimestamp":1787232600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUAJWSQX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651141619","title":"Polyrizon Adopts New Executive, Director Pay Policy with Bonus, Equity Caps","url":"https://stock-news.laohu8.com/highlight/detail?id=2651141619","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651141619?lang=en_us&edition=fundamental","pubTime":"2026-07-14 04:01","pubTimestamp":1783972895,"startTime":"0","endTime":"0","summary":"Polyrizon adopts new executive, director pay policy with bonus, equity capsPolyrizon adopted a compensation policy on July 13, 2026, setting caps for executive cash bonuses, equity awards, severance-s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL98Q2DQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648168888","title":"Polyrizon Says Nasarix Allergy Nasal Spray Meets All Biocompatibility Safety Standards in Testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2648168888","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648168888?lang=en_us&edition=fundamental","pubTime":"2026-07-02 21:06","pubTimestamp":1782997575,"startTime":"0","endTime":"0","summary":"Polyrizon  said Thursday that its proprietary Nasarix nasal spray met all required biological safety standards in a biocompatibility evaluation program.The testing followed internationally recognized standards and all key endpoints, including cytotoxicity, sensitization, irritation, and systemic toxicity, met acceptance criteria, the company said.The completion of the program is an \"important step toward potential commercialization of the product as a novel nasal barrier technology designed to help individuals suffering from seasonal allergies,\" the company said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648698502","title":"Polyrizon announces results from Nasarix biocompatibility evaluation program","url":"https://stock-news.laohu8.com/highlight/detail?id=2648698502","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648698502?lang=en_us&edition=fundamental","pubTime":"2026-07-02 19:40","pubTimestamp":1782992409,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) announced results from its biocompatibility evaluation program for its proprietary Nasarix Allergy Blocker nasal spray, with all r...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-announces-results-from-nasarix-biocompatibility-evaluation-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-announces-results-from-nasarix-biocompatibility-evaluation-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648044315","title":"Polyrizon Flags Release on Nasarix Biocompatibility Program Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2648044315","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648044315?lang=en_us&edition=fundamental","pubTime":"2026-07-02 19:32","pubTimestamp":1782991940,"startTime":"0","endTime":"0","summary":"Polyrizon flags release on NASARIX biocompatibility program resultsPolyrizon published a press release reporting successful biocompatibility results for NASARIX, supporting plans to advance toward a f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL3D6Kry:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2210150020.SGD","LU2095319765.USD","IE00BN0W2T93.GBP","SG9999014005.SGD","SG9999014039.USD","BK4112","BK4588","BK4585","SG9999014013.SGD","IE00BKPKM429.USD","PLRZ","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","BK4139","LU2210149790.SGD","SG9999014021.USD","LU0314104364.USD","NDAQ","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648504719","title":"Polyrizon Announces Successful Results for Nasarix™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2648504719","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648504719?lang=en_us&edition=fundamental","pubTime":"2026-07-02 19:32","pubTimestamp":1782991920,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nTUA6BXK9L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647720493","title":"Polyrizon Receives Approval for Human Trial of Nasarix Nasal Spray for Allergic Rhinitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2647720493","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647720493?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:46","pubTimestamp":1782740788,"startTime":"0","endTime":"0","summary":"Polyrizon  said Monday it received approval from the Institutional Review Board, or IRB, to conduct the first human clinical trial for its Nasarix nasal spray for seasonal allergic rhinitis.The approval confirms that the planned trial's study protocol, patient consent forms, and other materials meet IRB requirements, Polyrizon said.The trial is designed to assess the efficacy, safety, and tolerability of Nasarix compared with a saline spray in blocking airborne allergens, the company added.Polyrizon also said the approval is valid through June 17, 2027.Shares of Polyrizon were up more than 1% in early Monday trading.Price: 11.49, Change: +0.21, Percent Change: +1.86","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647569372","title":"Polyrizon receives central IRB approval for Nasarix","url":"https://stock-news.laohu8.com/highlight/detail?id=2647569372","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647569372?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:15","pubTimestamp":1782738915,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) announced it has received central IRB approval to begin its first human clinical trial for Nasarix, the company’s nasal spray desi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-receives-central-irb-approval-for-nasarix-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-receives-central-irb-approval-for-nasarix-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647374834","title":"Polyrizon Wins Central IRB Clearance to Start First Nasarix Allergy Blocker Human Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2647374834","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647374834?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:44","pubTimestamp":1782737058,"startTime":"0","endTime":"0","summary":"Polyrizon wins central IRB clearance to start first NASARIX allergy blocker human trialPolyrizon received central IRB clearance from BRANY to launch its first human trial of NASARIX nasal spray for se","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL53h9tc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014039.USD","LU2210149790.SGD","IE00BN0W2W23.USD","SG9999014005.SGD","SG9999014013.SGD","LU0314104364.USD","BK4139","BK4112","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","NDAQ","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4588","LU2095319765.USD","IE00BKPKM429.USD","PLRZ","SG9999014021.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647837100","title":"Polyrizon Makes Strong Progress: Receives Central Irb Approval for Its Allergy Blocker Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2647837100","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647837100?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:44","pubTimestamp":1782737040,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA17TTBM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644278745","title":"Polyrizon says U.S. publishes patent application for Trap & Target nasal drug delivery platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2644278745","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644278745?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:15","pubTimestamp":1781698515,"startTime":"0","endTime":"0","summary":"Polyrizon received notice of publication for U.S. patent application US 2024/0358741 A1 covering its Trap & Target mucoadhesive polymer nasal delivery platform.Application describes biocompatible compositions designed to form a durable film on nasal mucosa to improve retention and drug absorption.Platform targets intranasal delivery formats including sprays and gels, with potential use in localized or systemic administration via mucosal tissues.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL86QfLD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014005.SGD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","IE00BKPKM429.USD","IE00BN0W2V16.EUR","BK4588","LU2210150020.SGD","SG9999014039.USD","BK4585","IE00BN0W2W23.USD","LU0314104364.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","SG9999014021.USD","LU2210149790.SGD","PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644274527","title":"Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2644274527","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644274527?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:15","pubTimestamp":1781698500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nTUA96ZW9H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643051972","title":"Polyrizon Signs Agreements for Nasarix Human Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2643051972","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643051972?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:46","pubTimestamp":1781527597,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) has entered into agreements with a European university medical center and a clinical research organization to conduct a human study for its Nasarix allergy blocker, the company said M","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203937","title":"Polyrizon - Agrees With European Medical Center and Cro for Nasarix Human Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203937","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643203937?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:11","pubTimestamp":1781525485,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nFWN42N0BZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":65,"code":"91000000","status":"200"}]}}